A REAL-WORLD OBSERVATIONAL STUDY OF ETELCALCETIDE USE IN HEMODIALYSIS PATIENTS WITH SECONDARY HYPERPARATHYROIDISM IN EUROPE

被引：0
|
作者：
Louie, Karly [1 ]
Papadopoulou, Dorothea [2 ]
Hoffmann, Maxime [3 ]
Escola, Joaquin Manrique [4 ]
Kohnle, Matthias [5 ]
Cejka, Daniel [6 ]
Piccoli, Giorgina [7 ,8 ]
Rix, Marianne [9 ]
Boots, Johannes [10 ]
Pernat, Andreja Marn [11 ]
Torregrosa, Vicente [12 ]
Tsirtsonis, Kate [1 ]
Fouqueray, Bruno [13 ]
Floege, Juergen [14 ]
机构：
[1] Amgen Lth, Uxbridge, Middx, England
[2] Papageorgiou Hosp, Dept Nephrol, Thessaloniki, Greece
[3] Private Hosp La Louviere Ramsay Healthcare, Dept Nephrol & Dialysis, Lille, France
[4] Complejo Hosp Navarra, Nephrol Serv, Pamplona, Spain
[5] Nephrol Zentrum Mettmann, Mettmann, Germany
[6] Ordensklinikum Linz Elisabethinen, Dept Med 3, Nephrol, Transpantat Med,Rheumatol,Geriatr, Linz, Austria
[7] Ctr Hosp Le Mans, Le Mans, France
[8] Univ Torino, Turin, Italy
[9] Univ Hosp Copenhagen, Rigshosp, Dept Nephrol, Copenhagen, Denmark
[10] Maasstad Hosp, Dept Internal Med & Nephrol, Rotterdam, Netherlands
[11] Univ Med Ctr, Ljubljana, Slovenia
[12] Univ Barcelona, Hosp Clin, Nephrol & Renal Transplant Dept, Barcelona, Spain
[13] Amgen GmbH, Rotkreuz, Switzerland
[14] Rhein Westfal TH Aachen, Div Nephrol, Aachen, Germany
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2020年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
P0794
引用
收藏
页码：1122 / 1122
页数：1
相关论文
共 50 条
  • [21] LONG-TERM EFFICACY AND SAFETY OF ETELCALCETIDE IN HEMODIALYSIS PATIENTS WITH SEVERE SECONDARY HYPERPARATHYROIDISM
    Massimetti, Carlo
    Micarelli, David
    Feriozzi, Sandro
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 1717 - 1717
  • [22] Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis
    Wolf, Myles
    Block, Geoffrey A.
    Chertow, Glenn M.
    Cooper, Kerry
    Fouqueray, Bruno
    Moe, Sharon M.
    Sun, Yan
    Tomlin, Holly
    Vervloet, Marc
    Oberbauer, Rainer
    CLINICAL KIDNEY JOURNAL, 2020, 13 (01) : 75 - 84
  • [23] One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism
    Bushinsky, David A.
    Chertow, Glenn M.
    Cheng, Sunfa
    Deng, Hongjie
    Kopyt, Nelson
    Martin, Kevin J.
    Rastogi, Anjay
    Urena-Torres, Pablo
    Vervloet, Marc
    Block, Geoffrey A.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 (10) : 1769 - 1778
  • [24] EXPERIENCES WITH INTRAVENOUS ETELCALCETIDE IN LONG-TERM HEMODIALYSIS PATIENTS WITH SEVERE SECONDARY HYPERPARATHYROIDISM
    Pernat, Andreja Marn
    Gubensek, Jakob
    Cede, Ana Zupunski
    Knap, Bojan
    Persic, Vanja
    Trampuz, Barbara Vajdic
    Ponikvar, Jadranka Buturovic
    Ponikvar, Rafael
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33
  • [25] EFFECT OF SWITCHING FROM CINACALCET TO ETELCALCETIDE ON SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH HEMODIALYSIS; ESCORT TRIAL
    Kurokawa, Yuka
    Kaida, Yusuke
    Yano, Junko
    Takamiya, Yoshimi
    Otome, Takaomi
    Sugiyama, Miki
    Kojima, Aki
    Kumabe, Yuri
    Ito, Sakuya
    Kodama, Goh
    Nakamura, Nao
    Moriyama, Tomofumi
    Minami, Aki
    Nagata, Akiko
    Nakayama, Yosuke
    Shibata, Ryo
    Hazama, Takuma
    Fukami, Kei
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33 : 243 - 243
  • [26] IMPACT OF ETELCALCETIDE ON FGF23 LEVELS DURING THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS ON HEMODIALYSIS
    Wolf, Myles
    Block, Geoffrey
    Chertow, Glenn
    Cooper, Kerry
    Fouqueray, Bruno
    Moe, Sharon
    Sun, Yan
    Tomlin, Holly
    Vervloet, Marc
    Oberbauer, Rainer
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32
  • [27] REAL-WORLD EFFECTIVENESS OF ETELCALCETIDE VS. CINACALCET IN US HEMODIALYSIS PATIENTS: A FACILITY CALCIMIMETIC PREFERENCE APPROACH
    Karaboyas, Angelo
    Muenz, Daniel
    Hwang, Yunji
    Goodman, William
    Cheng, Sunfa
    Desai, Pooja
    Fox, Kathleen
    Robinson, Bruce
    Pisoni, Ronald
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36
  • [28] Long-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism
    Takashi Shigematsu
    Masafumi Fukagawa
    Keitaro Yokoyama
    Takashi Akiba
    Akifumi Fujii
    Motoi Odani
    Tadao Akizawa
    Clinical and Experimental Nephrology, 2018, 22 : 426 - 436
  • [29] Drug disposition model of radiolabeled etelcalcetide in patients with chronic kidney disease and secondary hyperparathyroidism on hemodialysis
    Wu, Liviawati
    Melhem, Murad
    Subramanian, Raju
    Wu, Benjamin
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2017, 44 (01) : 43 - 53
  • [30] Effect of switching from cinacalcet to etelcalcetide on secondary hyperparathyroidism in patients undergoing hemodialysis: an ESCORT trial
    Kurokawa, Yuka
    Kaida, Yusuke
    Hazama, Takuma
    Nakayama, Yosuke
    Otome, Takaomi
    Shibata, Ryo
    Ito, Sakuya
    Kodama, Goh
    Nakamura, Nao
    Kambe, Takatoshi
    Moriyama, Tomofumi
    Nagata, Akiko
    Minami, Aki
    Ando, Ryotaro
    Wada, Yoshifumi
    Sugiyama, Miki
    Usui, Michiaki
    Chiba, Michio
    Moriyama, Atsuo
    Ohara, Atsuko
    Miyazaki, Hiroshi
    Kakuma, Tatsuyuki
    Fukami, Kei
    RENAL REPLACEMENT THERAPY, 2020, 6 (01)
12345